The augmented expression of the cytidine deaminase gene by 5-azacytidine predicts therapeutic efficacy in myelodysplastic syndromes

5-Azacytidine (5AC), a hypomethylating agent, is clinically used for the treatment of patients with myelodysplastic syndromes (MDS). Cytidine deaminase (CDA) is a key enzyme in the detoxification of 5AC. We investigated whether the CDA expression could predict response to 5AC in MDS. Among leukemia-...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Murakami, Yuichi, Kimura, Yoshizo, Kawahara, Akihiko, Mitsuyasu, Shohei, Miyake, Hidetoshi, Tohyama, Kaoru, Endo, Yoshio, Yoshida, Nao, Imamura, Yutaka, Watari, Kosuke, Ono, Mayumi, Okamura, Takashi, Kuwano, Michihiko
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2019
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6481348/
https://ncbi.nlm.nih.gov/pubmed/31040918
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26784
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires